Nalmefene Induced Elevation in Serum Prolactin in Normal Human Volunteers: Partial Kappa Opioid Agonist Activity?

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Neuropsychopharmacology

• Publication date

  2005-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/sj.npp.1300811PMID 15988468
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Naloxone blockade of amphetamine place preference conditioning

  2005cited by this paper
• β-Endorphin-induced locomotor stimulation and reinforcement are associated with an increase in dopamine release in the nucleus accumbens

  2005cited by this paper
• Effect of the kappa opioid agonist R-84760 on cocaine-induced increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice.

  2004cited by this paper
• Effect of the endogenous kappa opioid agonist dynorphin A(1-17) on cocaine-evoked increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice.

  2004cited by this paper
• Cyclazocine: comparison to hydromorphone and interaction with cocaine

  2004cited by this paper
• Effect of the κ opioid agonist R-84760 on cocaine-induced increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice

  2004cited by this paper
• A Multi-site Dose Ranging Study of Nalmefene in the Treatment of Alcohol Dependence

  2004cited by this paper
• Mu-opioid receptor binding measured by [11C]carfentanil positron emission tomography is related to craving and mood in alcohol dependence.

  2004cited by this paper
• Effect of the endogenous κ opioid agonist dynorphin A(1–17) on cocaine-evoked increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice

  2004cited by this paper
• Chronic administration of nalmefene leads to increased food intake and body weight gain in mice.

  2004influential reference
• Naloxone effects on β-endorphin, cortisol, prolactin, growth hormone, HVA and MHPG in plasma of normal volunteers

  2004cited by this paper
• Effects of Naltrexone on the Subjective Response to Amphetamine in Healthy Volunteers

  2004cited by this paper
• Effects of Mixed-Action κ/μ Opioids on Cocaine Self-Administration and Cocaine Discrimination by Rhesus Monkeys

  2003cited by this paper
• Effects of mixed-action kappa/mu opioids on cocaine self-administration and cocaine discrimination by rhesus monkeys.

  2003cited by this paper
• Suppressed Prolactin Response to Dynorphin A1–13 in Methadone-Maintained Versus Control Subjects

  2003cited by this paper
• Comparison of the discriminative and neuroendocrine effects of centrally penetrating κ-opioid agonists in rhesus monkeys

  2002cited by this paper
• Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo–pituitary–adrenocortical axis

  2002cited by this paper
• Presynaptic mu-opioid receptors regulate a late step of the secretory process in rat ventral tegmental area GABAergic neurons.

  2002cited by this paper
• Enadoline and Butorphanol: Evaluation of κ-Agonists on Cocaine Pharmacodynamics and Cocaine Self-Administration in Humans

  2001cited by this paper
• Ethanol consumption and reward are decreased in µ-opiate receptor knockout mice

  2001cited by this paper
• The selective κ-opioid receptor agonist U50,488H attenuates voluntary ethanol intake in the rat

  2001cited by this paper
• The selective kappa-opioid receptor agonist U50,488H attenuates voluntary ethanol intake in the rat.

  2001cited by this paper
• Enadoline and butorphanol: evaluation of kappa-agonists on cocaine pharmacodynamics and cocaine self-administration in humans.

  2001cited by this paper
• Naltrexone and relapse prevention treatment for cocaine-dependent patients.

  2001cited by this paper
• μ-Opioid Receptor Knockout Mice Do Not Self-Administer Alcohol

  2000cited by this paper
• Kappa-opioid receptors and relapse-like drinking in long-term ethanol-experienced rats

  2000cited by this paper
• Prolactin: structure, function, and regulation of secretion.

  2000cited by this paper
• Naltrexone effects on ethanol consumption and response to ethanol conditioned cues in C57BL/6 mice

  2000cited by this paper
• Acute effects of nalmefene on LH, prolactin, and testosterone in male rhesus monkeys.

  2000cited by this paper
• Apparent efficacy of kappa-opioid receptor ligands on serum prolactin levels in rhesus monkeys.

  1999cited by this paper
• Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions.

  1999influential reference
• Acute "binge" cocaine increases mu-opioid receptor mRNA levels in areas of the rat mesolimbic mesocortical dopamine system.

  1999cited by this paper
• Opioid efficacy in a C6 glioma cell line stably expressing the human kappa opioid receptor.

  1999influential reference
• Apparent efficacy of κ-opioid receptor ligands on serum prolactin levels in rhesus monkeys

  1999cited by this paper
• Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.

  1998influential reference
• Use of positron emission tomography to measure the effects of nalmefene on D1 and D2 dopamine receptors in rat brain.

  1997cited by this paper
• κ2 Opioid Receptors in Limbic Areas of the Human Brain Are Upregulated by Cocaine in Fatal Overdose Victims

  1997cited by this paper
• The effects of spiradoline (U‐62066E), a κ‐opioid receptor agonist, on neuroendocrine function in man

  1997influential reference
• Increased mu opioid receptor binding detected by PET in cocaine–dependent men is associated with cocaine craving

  1996cited by this paper
• Kappa opioid inhibition of morphine and cocaine self-administration in rats.

  1995cited by this paper
• A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence.

  1994cited by this paper
• Repeated cocaine administration upregulates kappa and mu, but not delta, opioid receptors.

  1994influential reference
• Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes.

  1994cited by this paper
• Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors.

  1994cited by this paper
• Naltrexone in the treatment of alcohol dependence.

  1994cited by this paper
• U50,488, a κ opioid receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats

  1994cited by this paper
• Chronic repeated cocaine administration alters basal and opioid‐regulated adenylyl cyclase activity

  1993cited by this paper
• The effect of nalmefene on pulsatile secretion of luteinizing hormone and prolactin in men.

  1993cited by this paper
• Naltrexone and coping skills therapy for alcohol dependence. A controlled study.

  1992cited by this paper
• Evaluation of new compounds for opioid activity (1991).

  1992cited by this paper
• Chronic cocaine alters brain mu opioid receptors.

  1992cited by this paper
• Intravenous cocaine challenges during naltrexone maintenance: a preliminary study.

  1992cited by this paper
• Naltrexone in the treatment of alcohol dependence.

  1992cited by this paper
• Opioids excite dopamine neurons by hyperpolarization of local interneurons

  1992cited by this paper
• Evaluation of the sites of opioid influence on anterior pituitary hormone secretion using a quaternary opiate antagonist.

  1991cited by this paper
• Follow-up after a six-month maintenance period on naltrexone versus placebo in heroin addicts.

  1991cited by this paper
• The Effects of Opioid Peptides on Dopamine Release in the Nucleus Accumbens: An In Vivo Microdialysis Study

  1990cited by this paper
• Comparison of the duration of action of nalmefene and naloxone on the hypothalamic-pituitary axis of the rhesus monkey.

  1989influential reference
• Naloxone antagonism of corticotropin-releasing hormone stimulation of prolactin secretion in rhesus monkeys.

  1989influential reference
• Evaluation of new compounds for opioid activity.

  1988cited by this paper
• The psychopharmacologic and prolactin response after large doses of naloxone in man.

  1988cited by this paper
• Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats.

  1988cited by this paper
• Sustained effects of opioid antagonism during the normal human luteal phase.

  1988cited by this paper
• Effects of Naloxone Infusion on Plasma Levels of LH, FSH, and in Addition TSH and Prolactin in Males, Before and After Oestrogen or Anti-Oestrogen Treatment

  1986cited by this paper
• Anterior Pituitary Hormone Responses to a κ-Opioid Agonist in Man

  1986influential reference
• Antagonism by naltrexone of voluntary alcohol selection in the chronically drinking macaque monkey.

  1986cited by this paper
• Evaluation of new compounds for opioid activity (1985).

  1986influential reference
• Anterior pituitary hormone responses to a kappa-opioid agonist in man.

  1986cited by this paper
• Use of naltrexone as a provocative test for hypothalamic-pituitary hormone function.

  1986cited by this paper
• Hormonal effects of high dose naloxone in humans.

  1985cited by this paper
• Binding of a new opiate antagonist, nalmefene, to rat brain membranes.

  1985cited by this paper
• High-dose naloxone infusions in normals. Dose-dependent behavioral, hormonal, and physiological responses.

  1983cited by this paper
• Effects of Exogenous βh-Endorphin on Pituitary Hormone Secretionand Its Disappearance Rate in Normal Human Subjects*

  1981cited by this paper
• Effects of exogenous beta h-endorphin on pituitary hormone secretion and its disappearance rate in normal human subjects.

  1981cited by this paper
• Dopaminergic and serotonergic involvement in opiate-induced prolactin release in monkeys.

  1981influential reference
• Short-term hormonal effects of naloxone in man.

  1980cited by this paper
• Effects of heroin and naltrexone on plasma prolactin levels in man.

  1980cited by this paper
• Alteration of ethanol self-administration by naltrexone.

  1980cited by this paper
• Endocrine effects of naloxone-induced opiate receptor blockade.

  1980cited by this paper
• Morphine and endorphins modulate dopamine turnover in rat median eminence.

  1979cited by this paper
• Hormonal and other effects of naltrexone in normal men.

  1979cited by this paper
• MEDICAL COMPLICATIONS IN METHADONE PATIENTS *

  1978influential reference
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper
• Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

  1973cited by this paper
• A Controlled Study

  1966cited by this paper

• Nalmefene and naltrexone reduce alcohol intake via selective efficacy in subpopulations distinguished by behavioral and blood-based biomarkers

  2026cites this paper
• Biased Kappa-opioid Agonist Strategies in Pain Management: Approaches to Clinical Benefits with Reduced Adverse Effects

  2026cites this paper
• Use of nalmefene and behavioral counseling in patients with combined opioid and alcohol dependence

  2025cites this paper
• In Silico Evaluation of the Effect of Geometrical Configuration and Charge of Opioid Antagonists on Their Binding to Receptors

  2025cites this paper
• Nalmefene enhances the remyelinating ability of nalfurafine when administered therapeutically at very low doses during experimental autoimmune encephalomyelitis

  2025influential citation
• Searching for Synthetic Opioid Rescue Agents. 2: Identification of an Ultra-Potent Synthetic Opioid Rescue Agent.

  2025cites this paper
• Initial Experience With Nalmefene in Alcohol‐Related Liver Disease: A Real‐World Retrospective Study

  2025cites this paper
• Kappa opioid receptor control of motivated behavior revisited

  2025cites this paper
• Opioid antagonists: clinical utility, pharmacology, safety, and tolerability

  2024cites this paper
• Kratom Alkaloids for the Treatment of Alcohol Use Disorder.

  2024cites this paper
• Nalmefene, an opioid receptor modulator, aggravates atherosclerotic plaque formation in apolipoprotein E knockout mice by enhancing oxidized low-density lipoprotein uptake in macrophages

  2024cites this paper
• Effect of Preadministration of Nalmefene on Sufentanil-Induced Cough During Induction of General Anesthesia in Patients Undergoing Breast Surgery: A Double-Blind Randomized Controlled Trial

  2024cites this paper
• Navacaprant, a novel and selective kappa opioid receptor antagonist with no agonist properties implicated in opioid-related abuse.

  2024cites this paper
• Respiratory Depression Associated with Opioids: A Narrative Review

  2024cites this paper
• Safety, tolerability, pharmacokinetics, and pharmacodynamics of a novel kappa opioid receptor agonist ZYKR1: a randomized double-blind placebo-control phase 1 study in healthy adult human participants

  2023cites this paper
• Molecular Pharmacology Profiling of Phenylfentanil and Its Analogues to Understand the Putative Involvement of an Adrenergic Mechanism in Fentanyl-Induced Respiratory Depression.

  2023cites this paper
• The efficacy of nalmefene on anesthetic recovery of patients: a study protocol for a multicenter randomized controlled trial

  2023cites this paper
• Substance use disorders: a comprehensive update of classification, epidemiology, neurobiology, clinical aspects, treatment and prevention

  2023cites this paper
• Pharmacotherapy and gambling disorder: a narrative review

  2023cites this paper
• Prophylatic use of IV nalmefene to prevent epidural opioid-induced pruritus: A multicenter, randomized clinical trial.

  2023cites this paper
• Clinical moderators of response to nalmefene in a randomized-controlled trial for alcohol dependence: An exploratory analysis.

  2022cites this paper
• Pharmacological Treatment of Alcohol use Disorder in Patients with Psychotic Disorders: A Systematic Review

  2022cites this paper
• Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder

  2022cites this paper
• The effects of nalmefene on the impulsive and reflective system in alcohol use disorder: A resting-state fMRI study

  2022cites this paper
• Perspectives on the pharmacological management of alcohol use disorder: Are the approved medications effective?

  2022cites this paper
• The influence of opioid blockage on the sexual response cycle: A randomized placebo-controlled experiment with relevance for the treatment of Compulsive Sexual Behavior Disorder (CSBD).

  2022cites this paper
• Behandlung dissoziativer Symptome mit Nalmefen bei Patienten mit Borderline-Persönlichkeitsstörung und komplexer posttraumatischer Belastungsstörung

  2021cites this paper
• Pharmacologic and Clinical Considerations of Nalmefene, a Long Duration Opioid Antagonist, in Opioid Overdose

  2021influential citation
• Peptide Kappa Opioid Receptor Ligands and Their Potential for Drug Development.

  2021cites this paper
• Nalmefene, a Mu Opioid Receptor Antagonist/Kappa Opioid Receptor Partial Agonist, Potentiates Cocaine Motivation But Not Intake with Extended Access Self-Administration in Adult Male Mice.

  2021cites this paper
• Nalmefene attenuates neural alcohol cue-reactivity in the ventral striatum and subjective alcohol craving in patients with alcohol use disorder

  2021cites this paper
• Preclinical Studies on Nalfurafine (TRK-820), a Clinically Used KOR Agonist.

  2021cites this paper
• Neuroendocrine effects of naltrexone versus nalmefene in humans

  2020influential citation
• Unique Pharmacological Properties of the Kappa Opioid Receptor Signaling Through Gαz as Shown with BRET

  2020cites this paper
• Mesenchymal stem cells as new perspective for the treatment of alcohol use disorder

  2020cites this paper
• Long‐term safety and efficacy of nalmefene in Japanese patients with alcohol dependence

  2020cites this paper
• Unique Pharmacological Properties of the Kappa Opioid Receptor Signaling Through Gαz as Shown with Bioluminescence Resonance Energy Transfer

  2020cites this paper
• KOR Control over Addiction Processing: An Exploration of the Mesolimbic Dopamine Pathway.

  2020cites this paper
• Kappa Opioid Receptor Antagonists as Potential Therapeutics for Mood and Substance Use Disorders.

  2020cites this paper
• Kann eine forcierte Volumenaufnahme Alkoholcraving reduzieren?Eine randomisierte klinische Studie zum Einfluss des appetitregulierenden Peptids Ghrelin auf die Regulation von Suchtdruck bei alkoholabhängigen Patienten

  2020cites this paper
• Behavioral effects of the kappa opioid receptor partial agonist nalmefene in tests relevant to depression.

  2020cites this paper
• Kappa Opioid Receptors and Mu Opioid Receptors as Combined Targets for Medication Development for Alcoholism.

  2019cites this paper
• Current status of opioid addiction treatment and related preclinical research

  2019cites this paper
• Dopamine and opioid systems adaptation in alcoholism revisited: Convergent evidence from positron emission tomography and postmortem studies.

  2019cites this paper
• Stellungnahme Dachgesellschaft Sucht:

  2019cites this paper
• Drinking Levels and Profiles of Alcohol Addicted Rats Predict Response to Nalmefene

  2019cites this paper
• Signaling properties of structurally diverse kappa opioid receptor ligands: towards in vitro models of in vivo responses.

  2019cites this paper
• Safety of nalmefene for the treatment of alcohol use disorder: an update

  2019cites this paper
• Nalmefene in alcohol‐dependent patients with a high drinking risk: Randomized controlled trial

  2019cites this paper
• Clinically utilized kappa-opioid receptor agonist nalfurafine combined with low-dose naltrexone prevents alcohol relapse-like drinking in male and female mice.

  2019cites this paper
• Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140).

  2019cites this paper
• Antidepressant-like effects of 3-carboxamido seco-nalmefene (3CS-nalmefene), a novel opioid receptor modulator, in a rat IFN-α-induced depression model.

  2018cites this paper
• Involvement of Activated Brain Stress Responsive Systems in Excessive and “Relapse” Alcohol Drinking in Rodent Models: Implications for Therapeutics

  2018cites this paper
• Blocking of opioid receptors in experimental formaline-inactivated respiratory syncytial virus (FI-RSV) immunopathogenesis: from beneficial to harmful impacts

  2018cites this paper
• Structurally Related Kappa Opioid Receptor Agonists with Substantial Differential Signaling Bias: Neuroendocrine and Behavioral Effects in C57BL6 Mice

  2018cites this paper
• Stress, Drugs and Neuroscience : Neurobiological Effects of Social Stressors and Drug Exposure in Young and Adolescent Rats

  2018cites this paper
• Filamentous Hemagglutinin and Pertactin of Bordetella pertussis in BALB / c Mice View project Diagnosis of Candida Species Isolated from Patients with Vaginal Candidiasis and Healthy Individuals Based on Clinical Symptoms and Paraclinical Evidences View project

  2018cites this paper
• Synthesis of hybrid structures comprising diaziridine and cyclopropane rings in one molecule

  2018cites this paper
• Naltrexone and nalmefene attenuate cocaine place preference in male mice

  2018cites this paper
• Medications for substance use disorders (SUD): emerging approaches

  2017cites this paper
• Repeated Administration of Opra Kappa (LY2456302), a Novel, Short-Acting, Selective KOP-r Antagonist, in Persons with and without Cocaine Dependence

  2017cites this paper
• 4.21 – Endocrinological Effects of Drugs of Abuse

  2017cites this paper
• Continuous delivery of naltrexone and nalmefene leads to tolerance in reducing alcohol drinking and to supersensitivity of brain opioid receptors

  2017influential citation
• Nalmefene Reduces Reward Anticipation in Alcohol Dependence: An Experimental Functional Magnetic Resonance Imaging Study.

  2017cites this paper
• Management of precipitated opiate withdrawal syndrome induced by nalmefene mistakenly prescribed in opiate-dependent patients: a review for clinicians

  2017cites this paper
• Population pharmacokinetics of nalmefene in healthy subjects and its relation to μ-opioid receptor occupancy.

  2016cites this paper
• Lipophilic nalmefene prodrugs to achieve a one-month sustained release.

  2016cites this paper
• Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential

  2016cites this paper
• Gr upSM Opioid Receptor Antagonists and Alcohol Dependence Treatment PART

  2016cites this paper
• The "Cyclopropyl Fragment" is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules.

  2016cites this paper
• Treatment-refractory substance use disorder: Focus on alcohol, opioids, and cocaine.

  2016cites this paper
• Nalmefene is effective at reducing alcohol seeking, treating alcohol‐cocaine interactions and reducing alcohol‐induced histone deacetylases gene expression in blood

  2016cites this paper
• Clinical experience about an unexpected adverse event during nalmefene treatment in two patients with alcohol use disorder

  2016cites this paper
• Functional imaging of neural systems associated with alcohol reward and amphetamine toxicity

  2016cites this paper
• Tratamientos farmacológicos en la coadministración de alcohol y cocaína: efectos en la expresión de genes en el córtex prefrontal de la rata

  2016cites this paper
• Functional imaging of neural systems associated with alcohol reward and amphetamine toxicity

  2016cites this paper
• Distinct Effects of Nalmefene on Dopamine Uptake Rates and Kappa Opioid Receptor Activity in the Nucleus Accumbens Following Chronic Intermittent Ethanol Exposure

  2016influential citation
• Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy.

  2016influential citation
• Comparing Nalmefene and Naltrexone in Alcohol Dependence: Are there any Differences? Results from an Indirect Meta-Analysis

  2016cites this paper
• Human pharmacology for addiction medicine: From evidence to clinical recommendations.

  2016cites this paper
• Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders

  2015cites this paper
• Pharmacotherapy for alcohol dependence: A stratified approach.

  2015cites this paper
• Noribogaine is a G-protein biased κ-opioid receptor agonist.

  2015cites this paper
• Sex differences in acute hormonal and subjective response to naltrexone: The impact of menstrual cycle phase.

  2015cites this paper
• In Vitro and In Vivo Evaluations of PLGA Microspheres Containing Nalmefene

  2015cites this paper
• Können Alkoholabhängige ihre Trinkmengen durch eine Kombination von Medikamenten und Kurzinterventionen dauerhaft reduzieren

  2015cites this paper
• Treatment of cocaine craving with as-needed nalmefene, a partial κ opioid receptor agonist: first clinical experience.

  2015cites this paper
• Clinical Relevance of As-Needed Treatment with Nalmefene in Alcohol-Dependent Patients

  2015cites this paper
• [Neurobiology of alcohol and pharmacological aspects of nalmefene].

  2015cites this paper
• Liquid chromatography-mass spectrometry platform for both small neurotransmitters and neuropeptides in blood, with automatic and robust solid phase extraction

  2015cites this paper
• Individual differences in behavior, neurochemistry and pharmacology associated with voluntary alcohol intake

  2015cites this paper
• A Novel Method for Analyzing Extremely Biased Agonism at G Protein–Coupled Receptors

  2015cites this paper
• Nalmefene in Supporting Alcohol Reduction: Observations from a Clinical

  2015cites this paper
• Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders

  2015cites this paper
• The Effects of as-Needed Nalmefene on Patient-Reported Outcomes and Quality of Life in Relation to a Reduction in Alcohol Consumption in Alcohol-Dependent Patients

  2015cites this paper
• Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence: results from the Phase III clinical programme

  2015cites this paper
• Microsoft Word-80048204-file00.docx

  2015cites this paper
• Nalmefene and its use in alcohol dependence.

  2014cites this paper
• Nalmefene for the treatment of alcohol dependence: a current update.

  2014influential citation
• Potent Inhibition of Alcohol Self-Administration in Alcohol-Preferring Rats by a κ-Opioid Receptor Antagonist

  2014cites this paper